The PCR-based assays run on the company's Aries system, which itself received FDA clearance in October 2015.
A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.
The point-of-care test detects and distinguishes influenza A and B as well as respiratory syncytial virus in about 20 minutes.
The company will soon submit its ePlex instrument and respiratory pathogen panel for US Food and Drug Administration clearance.
Speakers at the CVS meeting in Florida last week spoke about the utility and effectiveness of sequencing approaches in the study of viruses.
The firm recently made strategic hires with commercialization experience in anticipation of bringing its handheld point-of-care device to market.
The company said sales of its XT-8 molecular diagnostics system were strong, despite a lighter-than-expected flu season.
The state department has implemented WGS protocols for influenza A and B to track drug resistance and to better understand how the virus changes from year to year.
Researchers discussed using WGS to predict antibacterial resistance, to inform influenza vaccine development, and to diagnose and build drug resistance profiles for tuberculosis.
In PLOS this week: role of fibrillarin during henipavirus infection, ancestry patterns in Bene Israel individuals, and more.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.